About Dr. Porter
Dr. Laura D. Porter is a member of the National Cancer Institute’s Gastrointestinal Steering Committee and a Patient Advocate on the National Comprehensive Cancer Network’s Colorectal Cancer Screening Panel. She also serves on several American Society of Clinical Oncology committees, including its Cancer Prevention Committee and its Targeted Agent and Profiling Utilization Registry Molecular Tumor Board.
She has reviewed cancer research grants as a patient representative for organizations including the U.S. Department of Defense and the Cancer Prevention and Research Institute of Texas. Dr. Porter also served on the FDA’s Oncologic Drugs Advisory Committee from 2016 to 2025.
Dr. Porter has served as a co-investigator and patient advocate on OPTIMISTICC, an international colorectal cancer microbiome research team funded through Cancer Research UK’s Grand Challenge program. She also taught patient engagement as a lecturer in the master’s program in health and science management at Universitat Autònoma de Barcelona.
Her Perspective as a Doctor and Cancer Survivor
As a cancer survivor and physician, Dr. Porter draws on both her medical and personal experience to offer a unique perspective on cancer treatment and survivorship. Doctors diagnosed her with stage 4 colon cancer in 2003, when she was 43 years old and in the second year of her pediatric residency. They gave her an 8% chance of living 5 years.
A year after her diagnosis, Porter became a Patient Advocate and medical consultant in the colon cancer community. She shared her survival journey and medical expertise online and in print during that time.
Porter later experienced two recurrences, in her ovary, liver, pancreas and abdominal lymph nodes. She went through many rounds of treatment and surgery and doctors declared her cancer-free in May 2006. She continues to serve the broader cancer community today.
Publications
- Porter, L.D. et al. (2025, July). Seven Actions Towards Advancing Patient Authorship and Collaboration in Peer-Reviewed Publications. Retrieved from link.springer.com/article/10.1007/s40271-025-00750-w
- Porter, L.D. et al. (2024, September). NCCN Guidelines Insights: Colorectal Cancer Screening. Retrieved from jnccn.org/view/journals/jnccn/22/7/article-p438.xml
- Porter, L.D. et al. (2023, May). Patient Advocates and Researchers as Partners in Cancer Research: A Winning Combination. Retrieved from ascopubs.org/doi/full/10.1200/EDBK_100035
- Porter, L.D. (2022, June). The Importance of Patient Engagement to Improve Healthcare Research and Safety. Retrieved from meridian.allenpress.com/innovationsjournals-JQSH
- Porter, L.D. et al. (2021, November). Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Retrieved from https://ascopubs.org/doi/10.1200/JCO.21.01440
- Porter, L.D. et al. (2021, November). Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Retrieved from https://ascopubs.org/doi/10.1200/JCO.21.01992
- Porter, L.D. et al. (2020, July). ctDNA Applications and Integration in Colorectal Cancer: An NCI Colon and Rectal-Anal Task Forces Whitepaper. Retrieved from doi.org/10.1038/s41571-020-0392-0
- Porter, L.D. et al. (2019, April). Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Retrieved from ascopubs.org/doi/full/10.1200/JCO.18.02142
- Porter, L.D. et al. (2019, March). Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Retrieved from bloodadvances.org/content/3/8/1197
- Porter, L.D. et al. (2017, March). A Stakeholder-Driven Approach to Improve the Informed Consent Process for Palliative Chemotherapy. Retrieved from doi.org/10.1016/j.pec.2017.03.024
- Porter, L.D. (2010, March). Knocking Out the Side Effects of Colorectal Cancer Treatment. Coping with Cancer.
- King, C.R., Swain, S.M., Porter, L., Steinberg, S.M., Lippman, M.E., & Gelmann, E.P. (1989, August). Heterogeneous Expression of erbB-2 Messenger RNA in Human Breast Cancer. Retrieved from pubmed.ncbi.nlm.nih.gov/2568168